Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Drug Does Not Improve Set of Cardiovascular Outcomes for Diastolic Heart Failure

Published: Tuesday, April 15, 2014
Last Updated: Tuesday, April 15, 2014
Bookmark and Share
NIH-supported study finds drug does appear to reduce hospitalizations for diastolic heart failure.

A drug that blocks the action of a key hormone did not significantly improve a set of cardiovascular outcomes for patients with diastolic heart failure, a condition in which the heart is stiffer than normal and has problems filling with blood, according to a study supported by the National Institutes of Health.

In terms of the study's primary aim, the results showed no difference in the overall combined endpoint treatments. The study did reduce the rate of heart failure hospitalizations, which was one of the endpoints, in the target population.

The drug, spironolactone, blocks the action of the hormone aldosterone, which is produced in excess in heart failure. The inexpensive generic drug currently is approved to treat patients with systolic heart failure, in which the heart muscle's pumping ability is reduced. There is no specific therapy for diastolic heart failure.

In the current trial, spironolactone did not improve the combined primary endpoints of cardiovascular death, hospitalization for heart failure, or aborted cardiac arrest. Aborted cardiac arrest is a stopped heart that is restarted by CPR or an implanted device.

NIH's National Heart, Lung, and Blood Institute (NHLBI) supported the work, which was published in the April 10 edition of the New England Journal of Medicine. The paper represents the primary results of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial.

Diastolic heart failure, also known as heart failure with preserved systolic function, is a common heart condition accounting for about half of all heart failure cases. The Centers for Disease Control and Prevention estimates that 5.7 million people in the United States have heart failure.

"Heart failure is the most common reason for hospital admissions in the Medicare population, and diastolic heart failure accounts for at least half of these admissions," said Dr. Bertram Pitt of the University of Michigan, Ann Arbor, TOPCAT's study chairman. "Given the high financial and societal costs of these hospitalizations, there is a critical need to find treatments to reduce them. However, no effective therapy for diastolic heart failure has been found to date."

The New England Research Institute and Brigham and Women's Hospital in Boston led the multi-center international research effort involving 3,445 participants, which makes it one of the largest diastolic heart failure trials to date. Researchers enrolled participants in 270 sites spread across the United States, Canada, Argentina, Brazil, the Republic of Georgia, and Russia. Trial participants were randomly placed on spironolactone or a matching placebo and followed for an average of three years.

For the spironolactone group, 319 participants experienced one of the primary outcomes versus 351 in the placebo group, a 9 percent reduction that did not reach statistical significance. For heart failure hospitalizations, 206 people in the spironolactone group were hospitalized versus 245 people in the placebo group, a statistically significant reduction of 16 percent.

"Although TOPCAT did not significantly decrease the combined endpoint or cardiovascular death, spironolactone is the first drug shown to reduce heart failure hospitalizations in this vulnerable population," said Brigham and Women's Hospital's Dr. Marc Pfeffer, the principal investigator.

Spironolactone showed no difference in other serious adverse events, such as dialysis, compared to placebo, although participants taking the drug had higher increased potassium levels than the control group. While use of spironolactone carries the risk of elevated blood potassium levels or reduced kidney function, these risks were low in TOPCAT and can be reduced in clinical practice with careful monitoring.

"This study is an important step in the effort to find effective treatments for diastolic heart failure patients," said Dr. Michael Lauer, director of the NHLBI's Division of Cardiovascular Sciences. "The study examined a broad cross-section of diastolic heart failure patients, and further data analysis may offer clues about sub groups that may particularly benefit from spironolactone treatment."

Initial analysis showed potentially different outcomes based on how a participant qualified for the study. Researchers used two methods to determine which patients with heart failure were eligible to enroll in the study. One method required looked for elevated levels of the hormone BNP, which is associated with more severe heart failure. The other method required looked at a person's history of heart failure hospitalization within the last year.

The study showed that participants enrolled via elevated BNP measurements who received spironolactone fared better in the composite of main outcomes than the BNP group enrolled in the placebo arm. Of the patients enrolled via the BNP criteria, there were 78 patients with events in the spironolactone arm and 116 patients with events in placebo group.

Further analysis showed significant geographic variation in event rates. For patients enrolled in Russia and the Republic of Georgia, 78 patients (10 percent) in the spironolactone arm and 71 patients (8 percent) in the placebo arm reached the composite primary endpoints. For patients in North and South America, 242 patients (27 percent) in the spironolactone arm and 280 patients (4 percent) in the placebo arm reached the composite primary endpoints.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
Thursday, May 05, 2016
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Wednesday, April 27, 2016
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Thursday, April 21, 2016
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Wednesday, April 20, 2016
Serotonin Transporter Structure Revealed
Researchers determined the 3-D structure of the serotonin transporter and visualized how two common antidepressants interact with the protein.
Wednesday, April 20, 2016
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
Wednesday, April 20, 2016
Submissions Open for the Cancer Moonshot Program
NCI opens online platform to submit ideas about research for Cancer Moonshot.
Tuesday, April 19, 2016
Migration Creates Cancer Cell Vulnerabilities
Scientists found that migration can damage cancer cells’ nuclei and DNA, requiring repairs for their survival. The results may open new avenues for targeting metastatic cancer.
Wednesday, April 13, 2016
NIH Sequences Genome of a Fungus
Researchers at the Institute have sequenced genome of human, mouse and rat Pneumocystis that cause life-threatening Pneumonia in immunosuppressed hosts.
Tuesday, April 12, 2016
NIH Awards Grants to Explore Vaccine Adjuvants
NIH awards six grants to explore how combination adjuvants improve vaccines.
Wednesday, April 06, 2016
Children With Cushing Syndrome May Have Higher Suicide Risk
Researchers at NIH have found that depression, anxiety and suicidal thoughts increase after treatment.
Wednesday, March 30, 2016
Experimental Vaccine Protects Against Dengue Virus
An experimental dengue vaccine protected all the volunteers who received it from infection with a live dengue virus.
Wednesday, March 30, 2016
Couples’ Pre-Pregnancy Caffeine Consumption Linked to Miscarriage Risk
Researchers at NIH have found daily multivitamin before and after conception greatly reduces miscarriage risk.
Friday, March 25, 2016
Study Finds Mindfulness Meditation Offers Relief For Low-Back Pain
Researchers at NIH have found that the MBSR and CBT may prove more effective than usual treatment in alleviating chronic low-back pain.
Wednesday, March 23, 2016
3-D Technology Enriches Human Nerve Cells For Transplant to Brain
This platform is expected to make transplantation of neurons a viable treatment for a broad range of human neurodegenerative disorders.
Friday, March 18, 2016
Scientific News
Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
Faster, Cheaper Way to Produce New Antibiotics
A novel way of synthesising a promising new antibiotic has been identified by scientists at the University of Bristol.
Process Contaminants in Vegetable Oils and Foods
Glycerol-based process contaminants found in palm oil, but also in other vegetable oils, margarines and some processed foods, raise potential health concerns for average consumers of these foods in all young age groups, and for high consumers in all age groups.
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Autism, Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Genetic Variant May Help Explain Why Labradors Are Prone To Obesity
A genetic variation associated with obesity and appetite in Labrador retrievers – the UK and US’s favourite dog breed – has been identified by scientists at the University of Cambridge. The finding may explain why Labrador retrievers are more likely to become obese than dogs of other breeds.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!